GALACTIC-HF Trial: Omecamtiv mecarbil

GALACTIC-HF Trial: Omecamtiv mecarbil GALACTIC-HF trial evaluated omecamtiv mecarbil, a cardiac myosin activator in heart failure with reduced ejection fraction [1]. The study had 8256 patients which included inpatients and outpatients with symptomatic heart failure with an ejection fraction of 35% or less. It was a placebo controlled trial of omecamtiv mecarbil in addition to standard heart failure therapy. Primary outcome was a composite of first heart failure event or death from cardiovascular causes. Heart failure event was defined as hospitalization or urgent hospital visit for heart failure. Over a median follow up of 21.8 months, primary outcome event occurred in 37% of the study group and 39.1% of the placebo group. Cardiovascular mortality was 19.6% in the study group and 19.4% in the placebo group. Kansas City Cardiomyopathy Questionnaire total symptom score did not capture any significant difference between the two groups on treatment. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) level was 10% lower in the omecamtiv mecarbil group at 24 weeks. Ventricular arrhythmia and ischemic events were similar in both groups. Previous studies on inotropic agents in heart failure have failed to improve outcome [2]. GALACTIC-HF trial also did not reduce mortality, though the primary outcome was better with omecamtiv mecarbil, driven by reduction in heart failure events. Omecamtiv mecarbil is a new class of drugs known as myotropes, which improve myocardial function by ...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs